表紙:消化性潰瘍:開発中の薬剤
市場調査レポート
商品コード
213113

消化性潰瘍:開発中の薬剤

Peptic Ulcers (Gastrointestinal) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 77 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.89円
消化性潰瘍:開発中の薬剤
出版日: 2021年11月30日
発行: Global Markets Direct
ページ情報: 英文 77 Pages
納期: 即納可能 即納可能とは
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

消化性潰瘍とは、食道・胃の内側や小腸の上端部に生じる開放創・潰瘍のことを指します。主な症状として、吐き気・嘔吐や、原因不明の体重減少、食欲の変動、腹痛などが挙げられます。主なリスク要因には、喫煙やアルコール依存症などがあります。主な治療法といて、抗生物質や酸遮断薬、制酸剤、プロトンポンプ阻害剤などがあります。

当レポートでは、世界各国での消化性潰瘍治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

消化性潰瘍の概要

治療薬の開発

  • 消化性潰瘍向けパイプライン製品:概要
  • 消化性潰瘍向けパイプライン製品:比較分析

各企業で開発中の消化性潰瘍治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

消化性潰瘍治療薬:開発中の製品の一覧(企業別)

消化性潰瘍治療薬の開発に従事している企業

  • Ache Laboratorios Farmaceuticos S/A
  • アステラス製薬
  • ChoDang Pharm Co., Ltd.
  • Daewoong Pharmaceutical Co., Ltd.
  • Kukje Pharmaceutical Industry Co., Ltd.
  • RaQualia Pharma Inc.
  • Sequella, Inc.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sinil Pharmaceutical Co., Ltd
  • Yooyoung Pharmaceutical Co., Ltd.

消化性潰瘍:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

消化性潰瘍治療薬:開発が休止状態の製品

消化性潰瘍治療薬:開発が中止された製品

消化性潰瘍関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース
  • ■付録

図表一覧

図表

List of Tables

List of Tables

  • Number of Products under Development for Peptic Ulcers, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Peptic Ulcers - Pipeline by Addpharma Inc, 2021
  • Peptic Ulcers - Pipeline by Axsome Therapeutics Inc, 2021
  • Peptic Ulcers - Pipeline by CalyGene Biotechnology Inc, 2021
  • Peptic Ulcers - Pipeline by Cinclus Pharma AG, 2021
  • Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
  • Peptic Ulcers - Pipeline by Edenbridge Pharmaceuticals LLC, 2021
  • Peptic Ulcers - Pipeline by FortuneRock (China) Ltd, 2021
  • Peptic Ulcers - Pipeline by Hunan Mingrui Pharmaceutical Co Ltd, 2021
  • Peptic Ulcers - Pipeline by Hunan Sailong Pharmaceutical Co Ltd, 2021
  • Peptic Ulcers - Pipeline by Ilyang Pharmaceutical Co Ltd, 2021
  • Peptic Ulcers - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2021
  • Peptic Ulcers - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2021
  • Peptic Ulcers - Pipeline by Korea Pharma Co Ltd, 2021
  • Peptic Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2021
  • Peptic Ulcers - Pipeline by PharmaKing Co Ltd, 2021
  • Peptic Ulcers - Pipeline by PharmGen Science Inc, 2021
  • Peptic Ulcers - Pipeline by RaQualia Pharma Inc, 2021
  • Peptic Ulcers - Pipeline by Sotex Pharm Firm, 2021
  • Peptic Ulcers - Pipeline by XuanZhu Biological Technology Co Ltd, 2021
  • Peptic Ulcers - Dormant Projects, 2021
  • Peptic Ulcers - Dormant Projects, 2021 (Contd..1)
  • Peptic Ulcers - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Peptic Ulcers, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC13170IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peptic Ulcers - Drugs In Development, 2021, provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape.

Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotic, acid blockers, antacids and proton pump inhibitors.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peptic Ulcers - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Peptic Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 3, 5, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peptic Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Peptic Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peptic Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peptic Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peptic Ulcers (Gastrointestinal)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peptic Ulcers (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peptic Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Peptic Ulcers - Overview
  • Peptic Ulcers - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Peptic Ulcers - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Peptic Ulcers - Companies Involved in Therapeutics Development
  • Addpharma Inc
  • Axsome Therapeutics Inc
  • CalyGene Biotechnology Inc
  • Cinclus Pharma AG
  • Daewoong Pharmaceutical Co Ltd
  • Edenbridge Pharmaceuticals LLC
  • FortuneRock (China) Ltd
  • Hunan Mingrui Pharmaceutical Co Ltd
  • Hunan Sailong Pharmaceutical Co Ltd
  • Ilyang Pharmaceutical Co Ltd
  • Jiangsu Aosaikang Pharmaceutical Co Ltd
  • Jiangsu Carephar Pharmaceutical Co Ltd
  • Korea Pharma Co Ltd
  • Kukje Pharmaceutical Industry Co Ltd
  • PharmaKing Co Ltd
  • PharmGen Science Inc
  • RaQualia Pharma Inc
  • Sotex Pharm Firm
  • XuanZhu Biological Technology Co Ltd
  • Peptic Ulcers - Drug Profiles
  • (meloxicam + esomeprazole) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AD-214 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CG-20043 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dexlansoprazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dexlansoprazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • famotidine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fexuprazan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • glycopyrrolate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ilaprazole DR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INT-2150 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IYIC-062 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KBP-3571 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • konolazan hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KP-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • linaprazan glurate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pantoprazole sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PMKS-005 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rabeprazole sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SFR-9X0123 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit COX-2 for Gastric Ulcers, Inflammation and Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tegoprazan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vonoprazan acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • WRDN-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptic Ulcers - Dormant Projects
  • Peptic Ulcers - Discontinued Products
  • Peptic Ulcers - Product Development Milestones
  • Featured News & Press Releases
  • Oct 22, 2021: Sihuan Pharmaceutical Holdings Group: New Drug Application of Xuanzhu Biopharm's drug Anaprazole Sodium accepted by NMPA
  • Mar 12, 2020: Gastroesophageal reflux disease new drug K-cap, Helicobacter pylori eradication indication
  • Feb 13, 2020: Sihuan Pharmaceutical Holdings Group: Commencement of phase III clinical trial in the PRC for self-developed innovative patented drug Anaprazole Sodium
  • Apr 25, 2019: Sihuan Pharm's innovative digestive system drug Anaprazole Sodium achieved early completion of patient recruitment for phase II clinical trial in China
  • Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
  • Jul 27, 2011: Ilyang Pharmaceuticals Obtains Patent For Ilaprazole
  • Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
  • Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
  • Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
  • Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
  • Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
  • Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
  • Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
  • Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
  • Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer